Stockwinners Market Radar for June 28, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:10 EDT LEDCO approves performance contract with AAON - The Longview Economic Development Corporation board of directors voted to approve a performance contract Friday for AAON, Inc. AAON will relocate the manufacturing of its SA Series self-contained unit product to its facility in Longview, 203 Gum Springs Road. The company will make a capital investment of $28M, including the construction of a new facility, equipment and the creation of 125 new jobs. The first phase of facility expansion, 195,000 sq. ft., will be completed by October 2020. The ultimate build-out of 422,000 sq. ft. is tentatively scheduled for 2022 completion.

17:31 EDT Celanese initiates shutdown of Ocotlan, Mexico manufacturing facility - Celanese Corporation announced a further consolidation of its global acetate manufacturing operations by initiating the shutdown of its manufacturing facility in Ocotlan, Jalisco, Mexico. The consolidation is designed to strengthen the company's competitive position, reduce fixed costs and align future production capacities with anticipated industry demand. Previously in June of 2018, Celanese announced it would discontinue the production of acetate tow at the Ocotlan facility. Today, Celanese is announcing that it will also discontinue the production of acetate flake at the Ocotlan site, essentially ceasing all manufacturing operations at the facility by October 31, 2019. The company will continue to serve its global acetate tow customers via its wholly owned facilities in Lanaken, Belgium, and Narrows, Virginia, USA, as well as through the company's acetate tow joint venture partners in China.

17:05 EDT Credicorp to acquire controlling interest in Bancompartir - Credicorp announced that it has reached an agreement to acquire 74.49% of the capital stock of Banco Compartir S.A., or Bancompartir, from a group of shareholders including Colsubsidio, Cafam, Comfandi, Comfenalco Cartagena, and Accion. Closing of the transaction, subject to certain regulatory approvals and other customary conditions, is expected to occur by Q4. Credicorp will pay approximately $80M for the 74.49% controlling interest in Bancompartir, subject to closing adjustments.

17:02 EDT North Sound Trading reports 9% passive stake in Cellectar Biosciences - In a regulatory filing, North Sound Trading disclosed a 9% stake in Cellectar Biosciences, which represents 850,000 common shares. The filing does not allow for activism.

16:53 EDT Wells Fargo provides more info on Strategic Execution and Operations Office - Wells Fargo & Company provided additional information about its newly formed Strategic Execution and Operations Office, which is focused on achieving operational excellence across businesses to enable the company to execute more effectively against its regulatory priorities and further drive transformation. Derek Flowers, a 21-year company veteran, will be head of the Strategic Execution and Operations Office. Flowers is an executive officer, a member of the company's Operating Committee, and reports to Interim CEO and President Allen Parker. The office is composed of several teams - including the Regulatory Consent Order and Risk Framework Execution Office, the Sales Practice Consent Order Office, Regulatory Relations, and the Business Process Management and Operational Design team - that are focused on the execution of critical business and risk programs and policies to drive operational excellence in the company's front line.

16:51 EDT AbbVie's Rapp acquires 7,500 common shares - In a regulatory filing, AbbVie director Edward J. Rapp disclosed the acquisition of 7,500 common shares of the company at a price of $67.30 per share.

16:38 EDT Retrophin announces FDA approval of Thiola EC - Retrophin announced that the FDA has approved 100 mg and 300 mg tablets of Thiola EC, a new enteric-coated formulation of Thiola, to be used for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine resulting in the formation of recurring cystine kidney stones. Thiola is expected to be available in July. The recommended initial dosage of Thiola in adult patients is 800 mg per day and in clinical studies the average dose of Thiola was approximately 1,000 mg, or 10 pills per day. The original formulation of Thiola 100 mg is recommended to be administered at least one hour before or two hours after meals. Thiola EC 100 mg and 300 mg tablets are recommended to be administered with or without food. Thiola EC tablets were approved through the 505 regulatory pathway which allows the FDA to reference previous findings of safety and efficacy for an already-approved product, combined with reviewing findings from further studies of the product.

16:33 EDT Santander Consumer ups quarterly div to 22c per share, authorizes $1.1B buyback - Santander Consumer USA Holdings lnc. announced its planned capital actions for the third quarter of 2019 through the second quarter of 2020, which are included in the 2019 Capital Plan of Santander Holdings USA, Inc., the majority stockholder of the company. The company's planned capital actions under the Capital Plan include: A quarterly cash dividend of 22c per share, an increase from 20c per share; and an authorization to repurchase up to $1.1B of the company's outstanding common stock through the end of the second quarter of 2020. The Share Repurchase Program, which has been authorized by the company's and SHUSA's boards of directors, is in addition to the company's previously announced $400M share repurchase program, which concluded with the repurchase of $86.8M of the company's common stock.

16:17 EDT Standex says New Albany warehouse experienced fire on June 26 - Standex International Corporation announced that the New Albany, Mississippi warehouse serving its Refrigerated Solutions Group Master-Bilt brand experienced a fire earlier this week on June 26. The warehouse, which is leased, comprises approximately 155,000 square feet. There were no injuries to the sixteen company personnel, although the warehouse facility and its contents have been substantially destroyed. The incident is currently under investigation by local authorities. While the adjacent manufacturing facilities did not suffer any damage and have resumed normal production, there was approximately $7 million of damage to the company's finished goods and approximately $1 million related to ancillary handling equipment. The company has insurance coverage associated with the damage to the inventory and equipment. "Thankfully, no one was hurt in this incident. I want to recognize the significant efforts of the emergency responders," said Standex Chief Executive Officer David Dunbar. "Our team is now working diligently to minimize the impact of this incident on our customers as we identify alternative locations for finished goods," said Dunbar.

16:11 EDT LendingClub announces reverse stock split effective date - LendingClub Corporation announced the effective date of a 1-for-5 reverse stock split of the Company's outstanding and treasury shares of its common stock, together with a proportionate reduction in the number of authorized shares of the company's common stock, that was approved by stockholders at the Company's annual meeting on June 5. The company expects that the reverse stock split will become effective at 4:30 pm ET on July 5 and that the company's shares of common stock will begin trading on a split adjusted basis on the NYSE when the market opens on July 8 under the company's existing symbol "LC."

16:10 EDT Harsco completes Clean Earth acquisition - Harsco Corporation announced that it has completed its previously announced acquisition of Clean Earth. Harsco expects the impact of this transaction to be accretive to the company's long-term financial targets.

16:07 EDT aTyr Pharma approves 1-for-14 reverse stock split - aTyr Pharma announced that its board of directors has approved a one-for-14 reverse stock split of its common stock that is scheduled to become effective after trading closes on June 28, 2019. The company's common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on July 1, 2019. The company's common stock will continue to trade under the symbol "LIFE." At the company's Annual Meeting of Stockholders held on May 8, 2019, the company's stockholders approved a proposal authorizing the company's board of directors to effect a reverse stock split in a range of 1:3 to 1:15 to help regain compliance with the Nasdaq minimum bid price requirement. The reverse stock split uniformly affects all issued and outstanding shares of the company's common stock. The reverse stock split will not alter any stockholder's percentage ownership interest in the company, except to the extent that the reverse stock split results in fractional shares. No fractional shares will be issued in connection with the reverse stock split. Any fractional share that would result from the reverse stock split will be rounded up to the nearest whole share.

16:02 EDT Francesca's announces 12-to-1 reverse stock split - Francesca's Holdings Corporation announced that its board of directors approved a reverse stock split of the company's common stock at a ratio of 12-to-1. Earlier on June 28, 2019, at the company's 2019 annual meeting of stockholders, the company's stockholders approved a reverse stock split of the company's common stock at a ratio not less than 5-to-1 and not greater than 35-to-1. The reverse stock split is expected to be effective after market close on July 1, 2019. The company's common stock is expected to begin trading on a split-adjusted basis on The Nasdaq Stock Market LLC at market open on July 2, 2019 under the new CUSIP number: 351793 203. The trading symbol for the company's common stock will remain "FRAN."

15:23 EDT Winmark vice chairman Steven Zola resigns - Winmark Corporation announced the submission by Steven C. Zola of his resignation from the position of President of Winmark Capital, as well as his resignation as Vice Chairman of the Board of Directors of Winmark Corporation. Brett D. Heffes stated "Mr. Zola joined Winmark at the early stages of building our leasing business and has made a significant contribution over the past fourteen years. We wish him well in the future." On an interim basis, Brett D. Heffes, Winmark Corporation's Chief Executive Officer will assume the additional responsibility of President of Winmark Capital.

14:51 EDT Wayne Savings Bancshares raises quarterly dividend 12% to 19c per share - Wayne Savings Bancshares has declared a cash dividend increase of 2c to 19c per share of the company's common stock for the quarter ending June 30, 2019. This represents a 12% increase over the prior quarter's dividend. The quarterly cash dividend will be paid on July 31, 2019 to stockholders of record as of July 17, 2019.

14:19 EDT Thermo Fisher sees some Q2 orders to be executed in Q3 due to data center issue - In a regulatory filing, Thermo Fisher disclosed that on June 26, an overheated component in an HVAC unit set off a fire suppressant system at one of Thermo Fisher's data centers. "While there was no fire, deployment of the suppressant gas temporarily affected certain systems for procurement and fulfillment, leading to some customers experiencing delays in placing orders and receiving shipments. Due to this situation, Thermo Fisher expects some second quarter orders to now be executed in the third quarter and will cover those details during its earnings call on July 24, 2019. The company does not expect any impact on its full year 2019 financial guidance. The company is working diligently to resolve this matter, and many systems at the data center have been restored," the filing stated.

13:54 EDT Vuzix files patent on augmented reality smart glasses - Vuzix Corporation announced it has filed a patent with the U.S. Patent & Trademark Office on next generation waveguide-based augmented reality smart glasses that are currently in development. The company said "These next generation smart glasses would incorporate multiple components of Vuzix IP and technology/ecosystem it has built around smart glasses."

13:00 EDT Famous Dave's announces partnership with Beyond Meat - Famous Dave's (DAVE) announced a partnership with Beyond Meat (BYND) and will be launching a test of plant-based protein menu items in mid-August. The test will roll out initially in five locations, four throughout Colorado and one in Minneapolis, the company announced.

12:00 EDT GTT Communications falls -7.4% - GTT Communications is down -7.4%, or -$1.44 to $18.02.

12:00 EDT China Green falls -9.5% - China Green is down -9.5%, or -58c to $5.54.

12:00 EDT GMS Inc. rises 8.9% - GMS Inc. is up 8.9%, or $1.76 to $21.46.

11:57 EDT Cemtrex regains Nasdaq listing compliance - Cemtrex Inc. announced that on June 28, 2019 the company received notification from the Qualifications Department of The Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5550a2, which concerns minimum bid price listing requirements. The company's shares will continue to be traded on The Nasdaq Stock Market under the Symbol CETX.

11:22 EDT PPG announces award of 5-year supply contract from U.S. Navy - PPG announced that it has been awarded a five-year, $78M contract by the U.S. Navy Military Sealift Command to provide coatings, solvents and technical services to MSC's fleet of approximately 125 ships. "This is a major win for the PPG marine team and showcases the value PPG can bring to customers through its broad range of products and deep expertise," said Juanjo Ardid, PPG vice president, protective and marine coatings, U.S. and Canada.

10:50 EDT Globalstar trading resumes

10:46 EDT Meredith appoints Farah Zaman as chief privacy officer - Meredith Corporation announced that Farah Zaman has been named chief privacy officer, effective immediately. Zaman will be responsible for leading Meredith's privacy compliance, education, and protection strategies across all businesses and locations. She will report to chief development officer and general counsel John Zieser. Prior to joining Meredith, Zaman served as senior global data privacy counsel for Colgate Palmolive.

10:36 EDT Globalstar to complete $62M shareholder bridge financing - Globalstar announced that its board of directors has approved a $62M non-convertible bridge facility to fund June 2019 principal and interest payments to lenders of its senior credit facility guaranteed by BPIFAE and to maintain compliance under the BPIFAE Facility. The new Bridge Facility, which is subject to completion of definitive documentation, is expected to close today and to be funded by multiple existing shareholders. The Bridge Facility will be fully subordinated to the BPIFAE Facility and will be senior to the existing Thermo Subordinated Loan. The facility will bear payable-in-kind interest and is expected to be replaced by a new second lien facility concurrent with a broader refinancing in the near-term. Jay Monroe, Executive Chairman of Globalstar, said: "The Bridge Facility represents the first step of a two-part refinancing of the company. We continue to work towards and are confident in our ability to complete a broader refinancing in the near-term. We look forward to announcing the comprehensive details of a transaction as soon as possible. We believe the resulting pro forma capital structure represents a significant improvement from the existing structure and will provide an extended runway for the company going forward. We expect this refinancing to allow the company to deliver on the extensive potential before us with respect to both the core satellite business and terrestrial spectrum opportunities."

10:17 EDT Pfizer presents initial clinical data on Phase 1b DMD gene therapy study - Pfizer (PFE) will present initial Phase 1b clinical data on PF-06939926, an investigational gene therapy to potentially treat Duchenne muscular dystrophy, or DMD, at the 25th Annual Parent Project Muscular Dystrophy Connect Conference in Orlando, FL. "These are preliminary data drawn from a small number of participants in an ongoing study," the company stated. The primary endpoint of the ongoing Phase 1b study is to assess the safety and tolerability of this investigational gene therapy. Secondary endpoints of the clinical study include measurement of expression of mini-dystrophin distribution within muscle fibers by immunofluorescence and concentration by liquid chromatography mass spectrometry. Pfizer aims to enroll approximately 12 boys with DMD who are ambulatory and aged 5 to 12. To date, 6 study participants ranging in age from 6 to 12 years have received the one-time intravenous dose of PF-06939926 at either 1E14 vector genomes/kilogram or 3E14 vg/kg, as quantified using an inverted terminal repeat-based quantitative polymerase chain reaction drug product titer assay. Preliminary results from open muscle biopsies of the biceps taken 2 months after dosing show detectable mini-dystrophin immunofluorescence signals with a mean of 38% positive fibers taken from participants who received PF-06939926 at 1E14 vg/kg and a mean of 69% positive fibers taken from participants who received PF-06939926 at 3E14 vg/kg. Preliminary safety results show that the most common adverse events suspected to be related to PF-06939926 are nausea, vomiting, decreased appetite, tiredness and/or fever, which were reported within a few days of dosing by 4 of 6 study participants. "As Pfizer continues to collect data from this ongoing open-label study in boys with DMD, it is also in the planning stages for a global, randomized, placebo-controlled Phase 3 study. This study is expected to begin in the first half of 2020 with commercial-scale manufacturing processes using multiple 2000-liter bioreactors. The anticipated Phase 3 study intends to leverage the learnings from the ongoing Phase 1b study in order to inform Pfizer's decisions regarding the optimal dose, assay, method of administration, concomitant medications, participant selection and safety monitoring," the company said.

10:17 EDT Globalstar trading halted, news pending

10:13 EDT Sarepta halted for volatility after jumping 10% to $142.59

10:12 EDT Sarepta trading halted, volatility trading pause

10:04 EDT Cummins acquires Hydrogenics for $15 per share in cash, or $290M - Cummins (CMI) announced that it has entered into a definitive agreement to acquire, through a wholly-owned subsidiary, all the issued and outstanding shares of Hydrogenics (HYGS) for $15.00 per share in cash, other than shares already owned by The Hydrogen Company, representing an enterprise value of approximately $290M. All non-interested directors of Hydrogenics have unanimously approved the transaction and recommends that Hydrogenics shareholders vote in favor of the transaction, the company added. "We are excited that Cummins has reached an agreement with Hydrogenics to welcome the employees and innovations of one of the world's leading fuel cell and hydrogen generation equipment providers to our company," said Tom Linebarger, Chairman and CEO, Cummins "We look forward to partnering closely with Hydrogenics' team in the coming weeks as we work toward closing the transaction. Upon closing, we will share more details about the acquisition and our strategy to offer a broad portfolio of power solutions to meet our customers' needs." As a part of the transaction, The Hydrogen Company, a wholly-owned subsidiary of L'Air Liquide, and Hydrogenics' current largest equity shareholder, will maintain its ownership in Hydrogenics. The closing of the acquisition of Hydrogenics is subject to the satisfaction of customary closing conditions. The transaction is expected to close in Q3 of 2019.

10:00 EDT GMS Inc. rises 8.1% - GMS Inc. is up 8.1%, or $1.59 to $21.30.

10:00 EDT EQT Corporation rises 8.3% - EQT Corporation is up 8.3%, or $1.20 to $15.63.

09:47 EDT Sogou falls -5.2% - Sogou is down -5.2%, or -22c to $4.05.

09:47 EDT Phoenix New Media falls -5.8% - Phoenix New Media is down -5.8%, or -21c to $3.43.

09:47 EDT Franklin Covey rises 6.1% - Franklin Covey is up 6.1%, or $2.00 to $35.00.

09:40 EDT Cummins subsidiary to buy outstanding Hydrogenics stake for $15 per share - Hydrogenics (HYGS) announced that it has entered into an arrangement agreement with Cummins (CMI) and Atlantis AcquisitionCo Canada Corporation, pursuant to which Atlantis, a subsidiary of Cummins, has agreed to acquire all of the outstanding common shares of the company other than shares owned by The Hydrogen Company, a wholly owned subsidiary of L'Air Liquide S.A., for $15.00 in cash per share. The Hydrogen Company has agreed to exchange its shares for shares of the purchaser pursuant to the transaction. The Hydrogen Company is Hydrogenics' largest shareholder, owning 3,537,931 shares, which represents approximately 18.6% of the issued and outstanding shares, the company noted. The transaction is structured as a statutory plan of arrangement under the Canada Business Corporations Act. The transaction is expected to be completed in Q3 2019.

09:27 EDT BeiGene gets approval to transition to general listing on HKEX - BeiGene announced that, following its application to the Stock Exchange of Hong Kong Limited, the Company has been approved for listing under Rule 8.05 as a company that meets specified revenue and market capitalization thresholds. BeiGene initially listed on the HKEX on August 8, 2018 under the biotech chapter of the Listing Rules. The Company now satisfies the revenue and market capitalization tests for listing outside of the biotech chapter. As a result of the approval, the "B" marker will be removed from the Company's stock symbol in the HKEX, and the Company's ordinary shares may become eligible for listing in the Hang Seng indices.

09:18 EDT Generex to submit application for up-lisiting in 'the coming days' - Generex Biotechnology provided guidance on the previously announced 1:1 GNBT stock dividend. The company said, "After discussing our listing with Nasdaq officials and our transfer agent Broadridge Financial Solutions, the dividend will be paid the day after our listing to the Nasdaq stock exchange, not on the same day as the listing as previously stated. In addition, Generex has been working on the application for the up-listing, and we have notified the Nasdaq that we will be submitting the application in the coming days." CEO Joe Moscato stated, "We are very close to submitting our application to Nasdaq for the up-list, and we have gotten positive input and direction from Nasdaq officials. The listing on the Nasdaq exchange is the last piece in our overall plan we put forth in January 2017 and ends with our 1:1 dividend to shareholders after we are listed. We are excited about the potential listing on Nasdaq, which will ensure our future and provide Generex with a significant benefit as it relates to raising capital and investor liquidity while building sustainable value for our shareholders. We will announce to our shareholders when the application is submitted."

09:09 EDT Aimmune submits application to European Medicines Agency for AR101 - Aimmune Therapeutics (AIMT) announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for AR101, an investigational biologic oral immunotherapy to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17. "This is an important milestone for us as a company, as well as for people across Europe living with peanut allergy, a growing worldwide health problem that significantly affects the quality of life of both patients and their families," said Jayson Dallas, CEO of Aimmune. "We are continuing to expand our organization across Europe to prepare for potential approval of AR101 in key markets and engaging in reimbursement discussions to expedite access for patients upon approval."

09:03 EDT Visa to acquire Verifi, terms not disclosed - Visa announced it has signed a definitive agreement to acquire Verifi. "The combination of Verifi's dispute resolution tools with Visa's suite of risk and fraud management solutions will give buyers and sellers intelligent, data-driven tools that foster collaboration, build trust, and improve the overall customer experience. With the addition of Verifi, Visa will extend its chargeback and dispute resolution capabilities to support a broad range of payments brands and partners across the ecosystem." Closing of the transaction is subject to required regulatory approvals and other customary closing conditions.

08:59 EDT Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Constellation Brands (STZ), up 7%... Avid Bioservices (CDMO), up 19%. ALSO HIGHER: La Jolla (LJPC), up 8% after announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted a positive opinion for La Jolla's marketing authorization application for Giapreza for the treatment of refractory hypotension in adults with septic or other distributive shock. DOWN AFTER EARNINGS: Smart Global (SGH), down 2%. ALSO LOWER: Sorrento Therapeutics (SRNE), down 26% after filing to sell common stock and warrants... PTC Therapeutics (PTCT), down 5% after the CHMP adopted a negative opinion of the extension of Translarna... PG&E (PCG), down 1% after responding to the to California Public Utilities Commission probe of 2017 Northern California wildfires... Wingstop (WING), down 2% after Stephens analyst Will Slabaugh downgraded shares to Equal Weight from Overweight, citing valuation.

08:34 EDT Q BioMed files application for Orphan Drug designation for QBM-001 - Q BioMed announced it has filed an application for Orphan Drug designation with the U.S. FDA's Office of Orphan Product Development for QBM-001, which is designed to treat pediatric minimally verbal autism. Q BioMed anticipates commencing clinical trials for QBM-001 in the first half of 2020, following submission of an Investigational New Drug application with the FDA later this year.

08:22 EDT Eve & Co announces first shipment of dried flower to Newfoundland - Eve & Co Incorporated announced the launch of its cannabis in dried flower format at select Newfoundland licensed cannabis retailers and on the Cannabis Newfoundland website on June 28, 2019.

08:18 EDT Replimune expects to initiate randomized Phase 2 trial in CSCC in the near term - "This past fiscal year has been incredibly productive for Replimune, with the advancement of several important clinical programs and a successful IPO that provides us with a solid financial foundation to continue to develop our portfolio of therapies," said Robert Coffin, Ph.D., co-founder, president and CEO of Replimune. "We are continuing to make significant strides as we work towards delivering on the promise of our oncolytic immuno-gene therapies. Importantly, we expect to initiate our randomized controlled registration-directed Phase 2 clinical trial in cutaneous squamous cell carcinoma in the near term, and to advance our second product candidate into the clinic with the initiation of a Phase 1 trial of RP2 later this year. The Phase 2 part of our clinical trial of RP1 in combination with nivolumab in four solid tumor types has also initiated, and we expect to be sharing the first set of clinical data from the Phase 1 part of the clinical trial in the fourth quarter of 2019."

08:15 EDT Opko Health says proposed LCD will allow Medicare coverage for 4Kscore test - OPKO Health announced that Novitas Solutions, Inc. has issued a new proposed local coverage determination for the 4Kscore test, with defined coverage criteria. Under the LCD, Medicare will reimburse the test for patients who meet the defined criteria. The 4Kscore test is a blood test used by health care professionals to assess a man's risk of having aggressive prostate cancer after an abnormal prostate specific antigen test result. OPKO has offered the 4Kscore test since 2014 in the U.S., Europe, and elsewhere.

08:13 EDT Health Insurance Innovations appoints Domenick DiCicco as CCO, counsel - Health Insurance Innovations announced the appointment of Domenick DiCicco as its chief compliance officer & counsel. DiCicco will work closely with HIIQ's executive leadership and regulatory compliance teams, comprised of experts in healthcare, strategic research, analytics, risk management, and technology. DiCicco served as global general counsel for Sedgwick.

08:10 EDT John Wiley raises quarterly dividend to 34c per share from 33c per share - John Wiley announced that its board has declared a quarterly cash dividend of 34c per share on its Class A and Class B Common Stock, payable on July 24 to shareholders of record on July 10. The 34c per share reflects an increase of 3% over the previous quarterly payout of 33c per share.

08:09 EDT ATA Inc. enters definitive agreement to acquire ACG - ATA Inc. announced that the Company has entered into a definitive agreement with Beijing Huanqiuyimeng Education Consultation Corp. and certain of its major shareholders and core management members for the acquisition of ACG. As previously announced in a press release on April 9, 2019, the Company had entered into framework agreements and certain conditional share purchase agreement and deposit agreement in connection with the acquisition of ACG, pursuant to which ACG and its major shareholders, including its founder Mr. Jun Zhang, agreed to negotiate exclusively with ATA for the acquisition of 100% equity interest of ACG. Under the terms of the Definitive Agreement, ATA will issue 9,360,000 ordinary shares to Arts Consulting Limited, the sole shareholder of ACG International Group Limited holding 69.04% equity interest in ACG, as consideration for 100% of shares of ACGIGL. Upon the closing of the transactions under the Definitive Agreement, ATA will become the sole shareholder of ACGIGL and indirectly hold 69.04% equity interest in ACG, and ArtsCL will become a holder of 16.5% of ATA's shares calculated on a fully diluted basis. The acquisition is expected to close before the end of August 2019, subject to the satisfaction of various conditions precedent in the Definitive Agreement, including but not limited to ATA receiving the business license, corporate seal and other important corporate documents of each and all subsidiaries wholly owned or controlled by ACGIGL, as well as the updated register of members and register of directors of ACGIGL reflecting that ATA has become its sole shareholder and that the individuals recognized or appointed by ATA have been named directors. In addition, the Company has entered into separate conditional share purchase agreements with certain of ACG's minority shareholders, pursuant to which ATA shall in aggregate acquire the remaining 30.96% equity interest in ACG from such minority shareholders. The closings of such acquisitions are respectively conditional upon the signing and effectiveness of the Definitive Agreement or the closing of the transactions under the Definitive Agreement.

08:06 EDT ProPetro Holding revises agreements with AFGlobal, secures order of three fleets - ProPetro Holding announced that it has entered into revised agreements with AFGlobal under which it will acquire one additional electrically powered DuraStim fleet in 2019 in addition to the two fleets previously announced. The company has also secured an option to purchase up to three additional fleets that will be exercisable through the end of 2020. The company also announced that XTO Energy have indicated their intent to be the first in the Permian Basin to deploy ProPetro's new electrically powered DuraStim fleets designed and manufactured by AFGlobal. ProPetro anticipates that the fleets should provide benefits, including a substantial reduction in fleet footprint and manpower, while extending the equipment life and reducing maintenance costs. The fleets are also expected to deliver a reduction in fuel consumption and emissions. During Q4 of 2018, ProPetro successfully tested one of the DuraStim pumps in the field alongside one of ProPetro's existing conventional fleets. The company currently expects to take delivery of the first DuraStim fleet in Q4. The revised agreement with AFGlobal amends and/or replaces previous contracts to purchase a total of six DuraStim fleets, including four DuraStim fleets that the company committed to purchase in April. Of approximately $24.5M of amounts previously paid to AFGlobal, a significant majority has been applied to the purchase price of a third DuraStim fleet, with the balance being utilized to acquire an option to purchase up to three additional fleets. The contracts relating to the first two DuraStim(R) fleets remain in place and the pricing terms for the third DuraStim fleet are consistent with those contracts. The option is exercisable through December 31, 2020 but will be subject to reduction beginning after June 30, 2020 and if the option is exercised, the option payment will be applied equally to the purchase price of each additional fleet ordered. ProPetro expects the first three fully deployed DuraStim fleets to cost an aggregate of approximately $180M of which approximately $97M has been spent to date and the remaining approximately $83M is expected to be spent during the remainder of 2019. ProPetro currently expects that any option fleets it acquires will have a comparable aggregate purchase price, subject to adjustment for increases in AFGlobal's major component costs, any design modifications and other market factors.

08:01 EDT KeyLeaf Life Sciences to become subsidiary of Canopy Growth - KeyLeaf Life Sciences is pleased to announce the next stage in its relationship with strategic partner Canopy Growth. KeyLeaf is becoming a wholly owned subsidiary of Canopy and will play a key role in Canopy's pursuit of leadership in cannabis extraction, purification and fractionation. This relationship will allow KeyLeaf to help shape the cannabis and hemp industry as part of a network of worldwide partners and progress KeyLeaf towards leadership in plant-based ingredients.

07:51 EDT Cytokinetics announces presentation of preclinical data for reldesemtiv - Cytokinetics (CYTK) announced that data from two preclinical studies of reldesemtiv were presented at the 2019 Annual Cure SMA Conference showing that the addition of reldesemtiv to treatment with SMN upregulators significantly increased muscle force in a mouse model of spinal muscular atrophy. In collaboration with Astellas (ALPMY), Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator, as a potential treatment for people with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue. In one preclinical study, a cohort of Hung Li SMA mice were treated with nusinersen alone or with nusinersen plus reldesemtiv. In another preclinical study, a cohort of Hung Li SMA mice were treated with either SMN-C1 alone or SMN-C1 plus reldesemtiv. In both studies, the mice were evaluated using an in vivo plantar flexor assay measuring isometric muscle force production in response to sciatic nerve stimulation of 10 Hz-200 Hz. Hung Li SMA mice treated with nusinersen showed increased body weight, tail length and muscle mass, confirming efficacy of treatment. In addition, nusinersen produced dose-dependent increases in muscle force in response to nerve stimulation. The administration of single doses of reldesemtiv further increased muscle force in response to sub-tetanic nerve stimulation in all groups of Hung Li SMA mice treated with nusinersen. At a submaximal stimulation frequency of 50 Hz, treatment of Hung Li SMA mice with nusinersen and reldesemtiv significantly increased muscle force by 290% relative to control Hung Li SMA mice in comparison to 100% relative to control in Hung Li SMA mice treated with nusinersen alone. Hung Li SMA mice treated with SMN-C1 showed increased survival, body weight and muscle mass also confirming the efficacy of treatment. In addition, treatment with SMN-C1 increased muscle force in response to nerve stimulation. The administration of single doses of reldesemtiv further increased muscle force in response to sub-tetanic nerve stimulation in Hung Li SMA mice treated with SMN-C1. At a submaximal stimulation frequency of 50 Hz, treatment of Hung Li SMA mice with SMN-C1 and reldesemtiv significantly increased muscle force by 320% relative to control Hung Li SMA mice in comparison to 32% relative to control in Hung Li SMA mice treated with SMN-C1 alone. In these studies, the addition of reldesemtiv to either nusinersen or SMN-C1 resulted in a leftward shift of the force-frequency curve, indicating an increase in calcium sensitivity of the muscle at submaximal stimulation frequencies and confirming the efficacy of fast skeletal muscle activation in muscle in conjunction with SMN upregulators. Augmentation of muscle force at submaximal stimulation frequencies may be relevant to activities such as breathing and walking. These data suggest that treatment with reldesemtiv in combination with an SMN upregulating therapy such as nusinersen or SMN-C1, may complement and further improve muscle function in SMA. Nusinersen is an approved anti-sense oligonucleotide therapy for SMA that increases production of Survival Motor Neuron protein. SMN-C1 is a small molecule therapy that increases SMN protein expression, similar to risdiplam, an investigational treatment in development for SMA.

07:43 EDT Constellation Brands expects Wine and Spirits transaction to close in 2Q20 - Guidance now assumes the Wine and Spirits Transaction closes at the end of second quarter fiscal 2020. As a result, the wine and spirits business now expects fiscal 2020 net sales and operating income to decline 20 - 25% and 25 - 30%, respectively.

07:40 EDT Constellation Brands raises FY20 operating cash flow target approx. $2.1B - Raises free cash flow projection to $1.2B-$1.3B from $1.1B-$1.2B.

07:31 EDT Chico's declares quarterly cash dividend of 8.75c per share - Chico's FAS announced that its Board of Directors declared a quarterly cash dividend of 8.75c per share of its common stock, a 3.0% increase over the dividend rate from September 2018. The dividend is payable on September 30 to Chico's FAS shareholders of record at the close of business on September 16.

07:09 EDT China Green announces 1-for-12 reverse stock split - China Green Agriculture announced that its Board of Directors and shareholders approved a reverse stock split of the Company's Common Stock at a ratio of 1-for-12. The reverse stock split is effective after market close on June 27, 2019. The Common Stock will begin trading on a split-adjusted basis on the New York Stock Exchange at the market open on June 28, 2019. At the Effective Time, every twelve issued and outstanding shares of the Company's Common Stock will be converted into one share of the Company's Common Stock. Once effective, the reverse stock split will reduce the number of shares of Common Stock issued and outstanding from approximately 47.82 million to approximately 3.98 million.

07:07 EDT Akorn announces launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5% - Akorn announced that it has launched its first-to-market generic of Loteprednol Etabonate Ophthalmic Suspension, 0.5%. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of post-operative inflammation following ocular surgery and the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

07:03 EDT Athenex strategically expands presence in Europe, Latin America - Athenex announced that the Company has strategically expanded its presence in Europe and Latin America to grow its global clinical research and development capacity. The Company believes these initiatives have the potential to enhance Athenex's capacity to conduct global clinical studies and support its regional marketing decision process. They are part of the Company's strategy to build on its current strong presence in U.S. and Asia, and help maximize the global potential of its pipeline. Athenex's oncology-focused pipeline currently has nine clinical candidates, including two drug candidates in Phase III development. In line with the Company's goal to expand its capability and bandwidth to optimize global development and commercialization of its pipeline products, Athenex has been evaluating operational opportunities in Europe and Latin America. As part of Athenex's strategy to establish operations in Europe, the Company has formed a subsidiary in the United Kingdom and established offices in Manchester. The Company is currently conducting clinical studies in the United Kingdom and intends to continue expanding its research and development capabilities in the region. In Latin America, Athenex recently entered into a definitive agreement to acquire certain assets of CIDAL Limited in exchange for shares of Athenex common stock, subject to customary closing conditions. CIDAL is a contract research organization with headquarters in Guatemala and operations in various countries in Latin America. CIDAL has provided important CRO services and support to Athenex, including for its Phase III study of oral paclitaxel and encequidar for metastatic breast cancer. The asset purchase is expected to strengthen Athenex's clinical research and operations capabilities and support the Company's clinical development worldwide.

07:02 EDT Sanofi announces CHMP recommends approval of Dupixent - The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Dupixent recommending extending its approval in the European Union to also include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. If approved, Dupixent would be the first biologic medicine approved in the EU to treat these patients. The positive CHMP opinion is based on clinical data from the LIBERTY AD program, including a pivotal Phase 3 trial and an open-label extension trial evaluating the efficacy and safety of Dupixent in adolescents with uncontrolled moderate-to-severe atopic dermatitis. A final decision on the Dupixent application by the European Commission is expected in the coming months. Dupixent is a fully-human monoclonal antibody that inhibits the signaling of interleukin-4 and interleukin-13, two proteins that play a central role in type 2 inflammation. Data from Dupixent clinical trials have shown that inhibiting IL-4 and IL-13 helps address the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis.

06:53 EDT PTC Therapeutics saysCHMP adopts negative opinion of extension of Translarna - PTC Therapeutic announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has completed their review of a proposed indication extension of Translarna for the treatment of patients with nonsense mutation Duchenne muscular dystrophy, or nmDMD, who are non-ambulatory. While the CHMP adopted a negative opinion of the extension, PTC was informed by EMA representatives that the European Public Assessment Report, or EPAR, will be updated to clarify that patients who start Translarna while ambulatory are not required to discontinue treatment after loss of ambulation. Translarna is currently indicated for ambulatory Duchenne patients who are over two years of age; the requested extension would have allowed for the inclusion of non-ambulatory patients in the label. PTC plans to request a re-examination of the procedure within the next two weeks and expects the new examination to last approximately 4 months. "While we are disappointed with the current outcome of the label expansion procedure and its impact on non-ambulatory patients with nonsense mutation Duchenne Muscular Dystrophy, we are pleased that patients on Translarna can remain on treatment after loss of ambulation," said Marcio Souza, COO, PTC Therapeutics. "We remain committed to work with the CHMP to clarify the open questions and are confident we will be able to demonstrate the pulmonary benefit of Translarna in non-ambulatory patients."

06:34 EDT Phoenix New Media announces update on Particle investment sale to Run Liang Tai - Phoenix New Media announced an update on the proposed sale of 32% of the total outstanding shares of Particle to Run Liang Tai and its designated entities for a total consideration of $448M in cash. As previously announced by the company, the company entered into a share purchase agreement, or SPA, with Run Liang Tai for the proposed transaction on March 22; the proposed buyers have paid cash deposit of $100M to the company and completion of the proposed transaction is subject to certain closing conditions specified in the SPA. The company sent a completion confirmation letter to Run Liang Tai on May 31 to confirm the satisfaction of all of the closing conditions. Run Liang Tai, however, disputed the satisfaction of certain closing conditions. The company is in discussion with Run Liang Tai in order to find an amicable resolution. However, there can be no assurance that the dispute will be resolved in the company's favor and there can be no assurance that the proposed transaction will ever be closed.

06:32 EDT La Jolla receives positive CHMP opinion for GIAPREZA - La Jolla Pharmaceutical announced that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion for La Jolla's Marketing Authorisation Application for GIAPREZA for the treatment of refractory hypotension in adults with septic or other distributive shock.

05:37 EDT JinkoSolar sees FY19 shipments 14GW-15GW

05:37 EDT JinkoSolar reports Q1 shipments 3,037 MW

05:32 EDT Amgen, UCB say CHMP adopted negative opinion of MAA for Evenity - Amgen and UCB announced that the companies have been informed the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a negative opinion on the Marketing Authorization Application for Evenity for the treatment of severe osteoporosis. The companies intend to submit a written notice for a re-examination by the CHMP. "We are disappointed with the CHMP opinion and believe that the body of evidence submitted supports a positive benefit:risk profile for EVENITY and its use in helping address the urgent need to improve post-fracture care and reduce the risk of painful, disabling fractures in postmenopausal women with severe osteoporosis at high risk of fracture," said Dr. Pascale Richetta, head of bone and executive vice president, UCB. "Together with Amgen we will seek a re-examination of the CHMP opinion. The re-examination process gives us the opportunity to clarify our position on the submitted data with the goal of making EVENITY available to postmenopausal women at high risk of fracture in the EU."

05:26 EDT Accenture enters AI, robotics collaboration with Mujin - Accenture and Mujin announced they are working together to deliver end-to-end intelligent service that uses artificial intelligence, or AI, and robotics to help accelerate digital transformation in the logistics industry. Accenture and Mujin will work together to deliver a comprehensive service ranging from logistics planning through technology implementation and operation. Businesses that have a logistics center, for example, will be able to implement a solution with a combination of Accenture's fulfillment service based on precise demand forecast as well as its deep industry insights, and Mujin's intelligent robot controller. Through the automation and visualization of warehouse operations, businesses will be able to leverage the visualized operation data to refine logistics plans and optimize delivery plans so that they accelerate transformation in their logistics.